2. Signaling Pathways
  3. Others
  4. Isotope-Labeled Compounds

Isotope-Labeled Compounds

Isotope-labeled compounds are chemical substances in which some atoms in their molecules are replaced by isotope atoms. The range of stable isotope products can cover from gases to complex molecules. Isotope-labeled compounds could provide a site-specific investigation of structures, making molecules easily detectable by mass spectrometry and NMR, and maintaining the physico-chemical properties of the target molecule at the same time. MCE isotope-labeled compounds are all stable isotope-labeled compounds and are non-radioactive labeled substances. MCE isotope-labeled compounds are unique tools for identifying and understanding biological and chemical processes. Stable isotope-labeled products are now getting more and more popular among scientists. The scope of application is gradually penetrating into various scientific fields, such as life sciences, food and medicine, agriculture, environment, geology, etc. Stable isotope-labeled compounds have a wide range of applications in the Life Science areas, such as Metabolomics, Proteomics, Clinical studies, Deuterium drugs, etc.

Isotope-Labeled Compounds Related Products (10876):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N2362S9
    DL-Alanine-13C2,15N2
    DL-Alanine-13C2,15N (DL-2-Aminopropionic acid-13C2,15N) is 13C and 15N labeled DL-Alanine. DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver.
    DL-Alanine-<sup>13</sup>C<sub>2</sub>,<sup>15</sup>N<sub>2</sub>
  • HY-120657S
    9-PAHSA-d4
    9-PAHSA-d4 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
    9-PAHSA-d<sub>4</sub>
  • HY-167586S
    18:0-22:6 PC-d9
    18:0-22:6 PC-d9 (1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine-d9) is deuterium labeled 18:0-22:6 PC.
    18:0-22:6 PC-d<sub>9</sub>
  • HY-13762S
    Tesmilifene-d4
    Tesmilifene-d4 is the deuterium labeled Tesmilifene (HY-13762). Tesmilifene is an antihistamine agent and a chemical sensitizer. Tesmilifene targets cytochrome P450, exhibits hormonal effects on DNA synthesis in MCF-7 cells, and stimulates the tumor growth in mouse/rat models. Tesmilifene overcomes multidrug resistance.
    Tesmilifene-d<sub>4</sub>
  • HY-125926S1
    2-Ketodoxapram-d4
    2-Ketodoxapram-d4 is deuterated labeled 2-Ketodoxapram.
    2-Ketodoxapram-d<sub>4</sub>
  • HY-32718S
    Pelitinib-d6
    Pelitinib-d6 (EKB-569-d6) is the deuterium labeled Pelitinib. Pelitinib (EKB-569) is an irreversible inhibitor of EGFR with an IC50 of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC50s of 282, 800, and 1255 nM, respectively.
    Pelitinib-d<sub>6</sub>
  • HY-78004S1
    1,2-Diphenylethane-d4
    1,2-Diphenylethane-d4 (Dibenzil-d4; s-Diphenylethane-d4; Bibenzyl-d4) is the deuterium labeled Bibenzyl (HY-78004).
    1,2-Diphenylethane-d<sub>4</sub>
  • HY-N0092S4
    Inosine-13C3
    Inosine-13C3 is a 13C-labeled Inosine that can be used in pharmacokinetic studies of Inosine. Inosine is an agonist of adenosine receptors A1R and A2AR with anti-inflammatory immunomodulatory, antinociceptive and neuroprotective effects.
    Inosine-<sup>13</sup>C<sub>3</sub>
  • HY-W011228S1
    9-Bromo-10-phenylanthracene-d13
    9-Bromo-10-phenylanthracene-d13 is the 13C-labeled 9-Bromo-10-phenylanthracene.
    9-Bromo-10-phenylanthracene-d<sub>13</sub>
  • HY-W777702
    2,2',3,4',5,5',6-Heptachloro-4-biphenylol-13C12
    2,2',3,4',5,5',6-Heptachloro-4-biphenylol-13C12 is 13C labeled 2,2',3,4',5,5',6-Heptachloro-[1,1'-biphenyl]-4-ol.
    2,2',3,4',5,5',6-Heptachloro-4-biphenylol-<sup>13</sup>C<sub>12</sub>
  • HY-76520S
    Sitaxsentan-13C6
    Sitaxsentan-13C6 (IPI 1040-13C6) is 13C labeled Sitaxsentan (HY-76520). Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension.
    Sitaxsentan-<sup>13</sup>C<sub>6</sub>
  • HY-B1283S
    Mephenesin-d3
    Mephenesin-d3 is deuterium labeled Mephenesin. Mephenesin is an NMDA receptor antagonist. Mephenesin is also a central muscle relaxant with antianxiety, muscle-paralyzing and anticonvulsant effects. Mephenesin acts directly on the skeletal muscle fibres to produce skeletal muscle relaxation. Mephenesin is promising for research of spasticity or painful muscle spasm.
    Mephenesin-d<sub>3</sub>
  • HY-B0554S1
    Norethindrone-13C2
    Norethindrone-13C2 (Norethisterone-13C2) is the 13C labeled Norethindrone (HY-B0554). Norethindrone is a female progestin approved by FDA for the treatment of endometriosis, uterine bleeding caused by abnormal hormone levels, and secondary amenorrhea.
    Norethindrone-<sup>13</sup>C<sub>2</sub>
  • HY-144414S
    N-Acetyl-S-ethyl-L-cysteine-d5
    N-Acetyl-S-ethyl-L-cysteine-d5 is the deuterium labeled N-Acetyl-S-ethyl-L-cysteine.
    N-Acetyl-S-ethyl-L-cysteine-d<sub>5</sub>
  • HY-70053S
    rac-Fesoterodine-d14 fumarate
    (Rac)-Fesoterodine-d14 fumarate is a labelled racemic Fesoterodine. Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKivalues of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB).
    rac-Fesoterodine-d<sub>14</sub> fumarate
  • HY-41826S1
    4-Bromo-1,1'-biphenyl-d9
    4-Bromo-1,1'-biphenyl-d9 is the deuterium labeled 4-Bromo-1,1'-biphenyl.
    4-Bromo-1,1'-biphenyl-d<sub>9</sub>
  • HY-B0104S3
    Glimepiride-d4-2
    Glimepiride-d4-2 (GliAmperide-d4-2) is deuterium labeled Glimepiride. Glimepiride (Glimperide) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED50 of 182 μg/kg.
    Glimepiride-d<sub>4</sub>-2
  • HY-W748346
    2,2′,3,3′,5,5′,6-Heptachloro biphenyl-13C12
    2,2′,3,3′,5,5′,6-Heptachloro biphenyl-13C12 is 13C labeled 2,2',3,3',5,5',6-Heptachloro-1,1'-biphenyl.
    2,2′,3,3′,5,5′,6-Heptachloro biphenyl-<sup>13</sup>C<sub>12</sub>
  • HY-15283AS
    (±)-Clopidogrel-d7 sulfate
    (±)-Clopidogrel-d7 (sulfate) is the deuterium labeled (±)-Clopidogrel sulfate.
    (±)-Clopidogrel-d<sub>7</sub> sulfate
  • HY-121877S
    Valnoctamide-d5
    Valnoctamide-d5 is the deuterium labeled Valnoctamide. Valnoctamide (Valmethamide), a derivative of valproate, suppresses benzodiazepine-refractory status epilepticus. Valnoctamide (Valmethamide) acts directly on GABAA receptors.
    Valnoctamide-d<sub>5</sub>